БХАРГАВА Панкадж (US),ЭСТЕВЕС У. Брук (US),РАЙАН Джон Л. (US)
申请号：
RU2012123970/15
公开号：
RU2012123970A
申请日:
2010.11.11
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating a tumor in a patient, comprising co-administering to the patient: (a) a dose of 1.5 mg per day tivozaniba and (b) a 25 mg dose of temsirolimus in nedelyu.2. A method according to claim 1, wherein tivozanib administered by repetitive scheme - one dose per day for three weeks followed by one week of no administration tivozaniba.3. A method according to claim 1, wherein the tumor is selected from the group consisting of renal cancer, colorectal tumors and neuroendocrine opuholi.4. A method according to claim 1, wherein the tumor is a cancer pochki.5. A method according to any one of claims 1-4, wherein tivozanib is a monohydrochloride monohydrate N- {2-chloro-4 - [(6,7-dimethoxy-4-quinolyl) -oxy] phenyl} -N - (5-methyl -3-isoxazolyl) mocheviny.6. Combination tivozaniba and temsirolimus for use in treating tumor tivozaniba administration of 1.5 mg to 25 mg per day and temsirolimus at nedelyu.7. Combination tivozaniba and temsirolimus according to claim 6, wherein tivozanib administered by repetitive scheme - one dose per day for three weeks followed by one week of no administration tivozaniba.8. Combination tivozaniba and temsirolimus according to claim 6, wherein the tumor is selected from the group consisting of renal cancer, colorectal tumors and neuroendocrine opuholi.9. Combination tivozaniba and temsirolimus according to claim 6, wherein the tumor is a cancer pochki.10. Combination tivozaniba and temsirolimus according to claim 7, wherein the tumor is selected from the group consisting of renal cancer, colorectal tumors and neuroendocrine opuholi.11. Combination tivozaniba and temsirolimus according to claim 7, wherein the tumor is a cancer pochki.12. Combination tivozaniba and temsirolimus according to any one pp.6-11, wherein tivozanib is a monohydrochloride monohydrate N- {2-chloro-4 - [(6,7-dimethoxy-4-Hing wherein tivozanib administered by repetitive scheme - one dose per day for three weeks followed by one week of no administration ti
